C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
Companies See Opportunity for the PrecivityAD2™ Blood Test to Transform the Clinical Standard of Care Through Early and Accurate Diagnosis of Alzheimer’s Disease March 06, 2024 07:00 AM Eastern Standard Time ST. LOUIS–(BUSINESS WIRE)–C₂N Diagnostics,…